Development of machine learning models for predicting early pregnancy outcomes based on β-hCG, progesterone, and estradiol

基于β-hCG、孕酮和雌二醇的机器学习模型在预测早期妊娠结局中的应用

阅读:2

Abstract

OBJECTIVE: This study aims to develop a machine learning model for predicting early pregnancy outcomes by combining baseline levels and dynamic changes of β-human chorionic gonadotropin (β-hCG), progesterone (P), and estradiol (E2). METHODS: This retrospective study screened out 421 patients treated at the Lanzhou University Second Hospital between March 2023 and August 2024. Feature selection was performed using Least Absolute Shrinkage and Selection Operator (LASSO) and Random Forest Recursive Feature Elimination (RF-RFE). Subsequently, we constructed a traditional logistic regression model and five machine learning models: Random Forest (RF), eXtreme Gradient Boosting (XGBoost), k-Nearest Neighbors (KNN), Multilayer Perceptron (MLP) neural network, and Support Vector Machine (SVM). Internal validity was assessed through 5-fold cross-validation. Model performance was measured by the area under the Receiver Operating Characteristic curve (AUC), accuracy, precision, sensitivity, and specificity. RESULTS: Among the 421 enrolled patients, 263 had ongoing pregnancies while 158 experienced early pregnancy loss (EPL). LR, RF, XGBoost, KNN, MLP, and SVM achieved AUCs of 0.750, 0.784, 0.750, 0.706, 0.755, and 0.749, respectively, with all accuracy and precision metrics exceeding 0.60. Notably, the RF model yielded optimal performance for EPL prediction, attaining the highest AUC (0.784), accuracy (0.729), and precision (0.724). CONCLUSION: Integrating dynamic changes in β-hCG, P, and E2 enables effective prediction of early pregnancy outcomes. The RF model exhibited optimal performance, highlighting its potential for clinical implementation as a risk stratification tool based on serial hormone monitoring.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。